The Technical Analyst
Mountain Crest [MCAD]
Exchange: NASDAQ Sector: Financial Services Industry: Shell Companies
Mountain Crest Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.92% $10.43
America/New_York / 29 okt 2021 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 247.65 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | N/A |
| SharesOutstanding: | 23.74 mill |
| Avg Daily Volume: | 0.101 mill |
| RATING 2022-02-09 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||
|---|---|---|
| 4/20 | 2/21 | |
| Revenue | n/a | n/a |
| Gr.Profit | n/a | n/a |
| Ebit | n/a | n/a |
| Asset | n/a | |
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -18.15 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE -25.74 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 10.42 - 10.44 ( +/- 0.12%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-01-07 | Haight Nelson | Sell | 0 | Common Stock |
| INSIDER POWER |
|---|
| 0.00 |
| Last 1 transactions |
| Buy: 0 | Sell: 0 |
Forecast:
01:40 - $10.03
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $10.43 (-4.92% ) |
| Volume | 0.347 mill |
| Avg. Vol. | 0.101 mill |
| % of Avg. Vol | 342.53 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MCAD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MCAD
Mountain Crest Acquisition Corp. II, a blank check company, intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.
Last 10 Buy Signals
Latest Press Releases
2021-10-12 20:00:00 - Press Release
Mountain Crest Acquisition Corp. Ii And Better Therapeutics, Inc. Announce Registration Statement Effectiveness And Scheduled Special Meeting To Approve Business Combination On October 27, 2021
New york and san francisco, oct. 12, 2021 (globe newswire) -- mountain crest acquisition corp. ii (nasdaq: mcad, “mountain crest ii”), a publicly-traded special purpose acquisition company and better therapeutics, inc. (“better therapeutics”), a prescription digital therapeutics (pdt) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that mcad's registration statement on form s-4 (file no. 333-255493) relating to the previously announced merger of mcad and better therapeutics has been declared effective by the u.s. securities and exchange commission as of october 12, 2021. mcad also announced that it will hold its special meeting of stockholders (the “special meeting”) on october 27, 2021 at 10:00 am eastern time to, among other things, allow its stockholders to vote to approve the proposed business combination with better therapeutics...
2021-09-10 08:00:00 - Press Release
Better Therapeutics To Participate In Lake Street's 5th Annual Best Ideas Growth (big5) Conference On September 14-15, 2021
San francisco--(business wire)--better therapeutics, inc. (“better therapeutics”), a prescription digital therapeutics (pdt) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, has been invited to present at the lake street's 5th annual best ideas growth (big5) conference, which is being held virtually on september 14-15, 2021. to receive additional information, request an invitation or to schedule a one-on-one meeting, please contact your lake st
2021-08-24 08:00:00 - Press Release
Better Therapeutics Expands Real-world Evidence Study Initiative With Addition Of Catalyst Health Network
San francisco--(business wire)--better therapeutics, inc. (“better therapeutics”), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with catalyst health network (“catalyst”), today announced the commencement of a real-world evidence study to evaluate the long-term effectiveness and healthcare utilization changes associated with the use of bt-001 for the treatment of type 2 diabetes. catalys
2021-07-29 15:00:00 - Press Release
Better Therapeutics And Colorado Prevention Center Clinical Research Launch Real-world Evidence Study Of Prescription Digital Therapeutic For Type 2 Diabetes
San francisco--(business wire)--better therapeutics, inc. (“better therapeutics”), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with colorado prevention center (cpc) clinical research, affiliated with the university of colorado anschutz medical campus, today announced the commencement of a real-world evidence study to evaluate the long-term effectiveness and healthcare utilization chang
2021-04-14 08:01:00 - Press Release
Better Therapeutics Launches Real World Evidence Study Of Prescription Digital Therapeutic For Type 2 Diabetes
San francisco--(business wire)--better therapeutics, inc. (“better therapeutics”), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the commencement of a real-world evidence study with steward health care to evaluate the long-term effectiveness and cost of care impact associated with the use of bt-001 for the treatment of type 2 diabetes. bt-001 is an investigational, prescription digital
Latest News
2021-10-12 20:00:00 - GlobeNewsWire
Mountain Crest Acquisition Corp. II and Better Therapeutics, Inc. Announce Registration Statement Effectiveness and Scheduled Special Meeting to Approve Business Combination on October 27, 2021
NEW YORK and SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Mountain Crest Acquisition Corp. II (NASDAQ: MCAD, “Mountain Crest II”), a publicly-traded special purpose acquisition company and Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, today announced that MCAD's registration statement on Form S-4 (File No. 333-255493) relating to the previously announced merger of MCAD and Better Therapeutics has been declared effective by the U.S. Securities and Exchange Commission as of October 12, 2021. MCAD also announced that it will hold its special meeting of stockholders (the “Special Meeting”) on October 27, 2021 at 10:00 am Eastern Time to, among other things, allow its stockholders to vote to approve the proposed Business Combination with Better Therapeutics...
2021-09-10 08:00:00 - Business Wire
Better Therapeutics to Participate in Lake Street's 5th Annual Best Ideas Growth (BIG5) Conference on September 14-15, 2021
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics (PDT) company developing cognitive behavioral therapy to address root causes of cardiometabolic diseases, has been invited to present at the Lake Street's 5th Annual Best Ideas Growth (BIG5) Conference, which is being held virtually on September 14-15, 2021. To receive additional information, request an invitation or to schedule a one-on-one meeting, please contact your Lake St
2021-08-24 08:00:00 - Business Wire
Better Therapeutics Expands Real-World Evidence Study Initiative With Addition of Catalyst Health Network
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with Catalyst Health Network (“Catalyst”), today announced the commencement of a real-world evidence study to evaluate the long-term effectiveness and healthcare utilization changes associated with the use of BT-001 for the treatment of type 2 diabetes. Catalys
2021-07-29 15:00:00 - Business Wire
Better Therapeutics and Colorado Prevention Center Clinical Research Launch Real-World Evidence Study of Prescription Digital Therapeutic for Type 2 Diabetes
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, in partnership with Colorado Prevention Center (CPC) Clinical Research, affiliated with the University of Colorado Anschutz Medical Campus, today announced the commencement of a real-world evidence study to evaluate the long-term effectiveness and healthcare utilization chang
2021-04-14 08:01:00 - Business Wire
Better Therapeutics Launches Real World Evidence Study of Prescription Digital Therapeutic for Type 2 Diabetes
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced the commencement of a real-world evidence study with Steward Health Care to evaluate the long-term effectiveness and cost of care impact associated with the use of BT-001 for the treatment of type 2 diabetes. BT-001 is an investigational, prescription digital